Trials / Completed
CompletedNCT01571596
An Extension Study of KRN23 in Adults With X-Linked Hypophosphatemia
An Open-Label, Long-Term, Extension Study to Evaluate the Safety and Efficacy of KRN23 in Adult Subjects With X-Linked Hypophosphatemia
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 23 (actual)
- Sponsor
- Kyowa Kirin Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to assess the safety and efficacy of repeated subcutaneous (SC) injections of KRN23 in adult subjects with X-Linked Hypophosphatemia (XLH).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | KRN23 | Subjects will receive escalating doses of KRN23 administered by SC injection every 28-days (up to 12 doses) based on a dosing algorithm and discretion of Investigator and Sponsor. |
Timeline
- Start date
- 2012-02-01
- Primary completion
- 2013-09-01
- Completion
- 2014-06-01
- First posted
- 2012-04-05
- Last updated
- 2024-06-18
- Results posted
- 2021-02-17
Locations
6 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT01571596. Inclusion in this directory is not an endorsement.